Navigation Links
Imagenetix Reports Results of Offer to Extend Warrants
Date:12/21/2007

Majority of Warrant Holders Subscribe to Offering

SAN DIEGO, Dec. 21 /PRNewswire-FirstCall/ -- Imagenetix, Inc. (OTC Bulletin Board: IAGX), announced today that 53 warrants totaling 3,110,710 warrant shares were extended until October 23, 2010 in response to the offering. The warrants extended had exercise prices from $1.00 to $2.00.

The warrants holder's paid the Company $.05 per warrant share for the extension resulting in the Company receiving, approximately $155,000. During the offering period 146 warrant shares were exercised and 539,755 expired.

Along with the extension of time the terms of the call provisions were changed. The Company now has the right to call any series of its warrants if the stock should trade at a 20% premium to the exercise price of the warrant for 10 business days.

Mr. William Spencer, President of Imagenetix, commenting on the offering said, "I was extremely pleased that so many of our long term supporters took advantage of this offering. The change in the call provision will allow us to raise additional capital, as the stock price increases, which we can use to expand our branding efforts and for the development of new products."

About Imagenetix

Based in San Diego, California, Imagenetix, (OTC Bulletin Board: IAGX) is an innovator of scientifically tested, natural-based, proprietary bioceutical products developed to enhance human health on a global basis. Imagenetix develops, formulates and private-labels propriety over-the-counter topical creams, skincare products and nutritional supplements to be marked globally through multiple channels of distribution. In addition, the company develops patentable compounds for entering into licensing agreements with pharmaceutical partners. Imagenetix is the creator of Inflame Away(TM)- Celadrin(R), which has been clinically tested to relieve osteoarthritis pain and significantly improve joint health. For more information, please visit, http://www.imagenetix.net.

This document contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements are subject to risks and uncertainties that could cause actual results to vary materially from those projected in the forward-looking statements. The company may experience significant fluctuations in future operating results due to a number of economic, competitive, and other factors, including, among other things, the size and timing of customer contracts, new or increased competition, changes in market demand, and seasonality of purchases of the company's products and services. These factors and others could cause operating results to vary significantly from those in prior periods and those projected in forward-looking statements. Additional information with respect to these and other factors, which could materially affect the company and its operations, are included in certain forms the company has filed and will periodically file with the Securities Exchange Commission.


'/>"/>
SOURCE Imagenetix, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
2. Dr. Thomas Van Dyke Renowned Boston University Professor Joins Imagenetixs Medical Advisory Board
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. QMed, Inc. Reports July Medicare SNP Enrollments
5. Phlo Affiliate Reports Expanded Coverage to Oregon Border
6. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
7. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
8. Carrington Reports Second Quarter 2007 Results
9. Avitar Reports Third Quarter Financial Results for Fiscal 2007
10. Response Genetics Reports Second Quarter 2007 Financial Results
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... MD (PRWEB) , ... April 27, 2016 , ... ... Greg Lamka, PhD to its Scientific Advisory Board. Dr. Lamka will assist PathSensors ... plant pathogen detection. , PathSensors deploys the CANARY® test platform for the ...
(Date:4/27/2016)... PARIS , April 27, 2016 ... system disorders, today announces the appointment of Catherine Moukheibir as ... succeed MedDay,s previous Chairman, Jean Jacques Garaud , who ... The change is effective immediately. Catherine started her ... Boston and London .  She ...
(Date:4/26/2016)... ... April 26, 2016 , ... The European Patent Office (EPO) today ... three finalists for the European Inventor Award 2016 in the category "Non-European countries." The ... at a ceremony in Lisbon on June 9th. , The human capacity to walk ...
(Date:4/26/2016)... ... April 26, 2016 , ... BioFactura, Inc ., a ... round of financing. Healthy investor interest drove significant oversubscription of the original $1.5M ... known as biosimilars, to the advanced preclinical stages. , Chief Executive Officer and President, ...
Breaking Biology Technology:
(Date:4/28/2016)... Sweden , April 28, 2016 First ... M (139.9), up 966% compared with the first quarter of 2015 ... profit totaled SEK 589.1 M (loss: 18.8) and the operating margin ... 7.12 (loss: 0.32) Cash flow from operations was SEK ... The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:3/29/2016)... RATON, Florida , March 29, 2016 ... or the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are ... DNA in ink used in a variety of writing ... theft. Buyers of originally created collectibles from athletes on ... through forensic analysis of the DNA. ...
Breaking Biology News(10 mins):